Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pharmacokinetic study of flumatinib in chronic phase chronic myeloid leukemia
ChiCTR2100044700Phase 3Completed
- Sponsor
- National Clinical Research Center for Hematological Disease
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of Flumatinib in chronic myelogenous leukemia (CML) (2 cohorts), sponsored by National Clinical Research Center for Hematological Disease. Primary endpoint: Drug concentration-time curve. Started Dec 2016; status: completed.
02
Drugs
Flumatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR2100044700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044700.